EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events

Ilya Gurevic, Loic Meudec, Xavier Mariette, Gaetane Nocturne, Sara S McCoy iD

PLOS One · 16.06.2025 · 20 (6) · e0311706

DOI: 10.1371/journal.pone.0311706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 16.06.2025. Verfasst von Ilya Gurevic und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our objective was to define the effect of JAK inhibitor (JAKinib) withdrawal on JAK/STAT biochemical response in the context of systemic rheumatic diseases.

Methods

We tested Type I (bind kinase active conformation) and Type II (bind kinase inactive conformation) JAKinibs in vitro using mesenchymal stromal cells (MSCs) and human umbilical vein endothelial cells (HUVECs). We translated our findings in vivo studying NK cells from rheumatoid arthritis (RA) patients treated with Type I JAKinibs or methotrexate.

Results

Type I JAKinibs (ruxolitinib and baricitinib) increased phosphoJAK1 (pJAK1) and pJAK2 of IFNγ-stimulated MSCs and HUVECs in a time- and dose- dependent manner, with effect peaking after 24 hours. As expected, pSTAT1 was completely suppressed by JAKinibs. We found a marked and rapid increase of pSTATs upon discontinuation of Type I JAKinibs, that occurred to a lesser extent after Type II JAKinib withdrawal. Type I JAKinib withdrawal increased interferon and urokinase expression when compared to Type II JAKinib withdrawal. We found NK cells from RA patients taking Type I JAKinibs had a pro-inflammatory profile after JAKinib withdrawal compared to patients on methotrexate.

Conclusions

Type I JAKinibs paradoxically accumulate functionally defective pJAK. Upon withdrawal, the primed pJAKs are de-repressed and initiate a pSTAT signaling cascade, resulting in high interferon and urokinase. Type II JAKinibs do not cause pJAK accumulation, pSTAT cascade, and subsequent pro-inflammatory transcripts. The resultant cytokines and proteins produced from this cascade might explain adverse cardiac outcomes. Thus, JAKinib withdrawal is a possible mechanism contributing to the major adverse cardiac events described with JAKinib therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsHumansArthritis, RheumatoidAzetidinesPyrimidinesKiller Cells, NaturalPyrazolesHuman Umbilical Vein Endothelial CellsMesenchymal Stem CellsPurinesNitrilesSulfonamidesMethotrexateInflammationMaleMiddle AgedSTAT1 Transcription FactorFemaleSignal Transduction

Substanzen

Janus Kinase InhibitorsAzetidinesbaricitinibPyrimidinesPyrazolesPurinesNitrilesSulfonamidesruxolitinibMethotrexate

Autor:innen und Institutionen

  • Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.
  • Center for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR, Université Paris-Saclay, Le Kremlin-Bicêtre, Paris, France.
  • Université Paris-Saclay, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR, Le Kremlin-Bicêtre, Paris, France.
  • Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, Department of Rheumatology, Le Kremlin Bicêtre, France.

ORCID-Profile: Sara S McCoy

Förderung

  • NIDCR NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • National Institute of Dental and Craniofacial Research
  • National Center for Advancing Translational Sciences
  • Pfizer Foundation

Zitieren

APA

Gurevic, I., Meudec, L., Mariette, X., Nocturne, G., & McCoy, S. S. (2025). JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events. PLOS One, 20(6), e0311706. https://doi.org/10.1371/journal.pone.0311706

Vancouver

Gurevic I, Meudec L, Mariette X, Nocturne G, McCoy SS. JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events. PLOS One. 2025;20(6):e0311706. doi:10.1371/journal.pone.0311706

BibTeX
@article{Gurevic2025,
  author = {Gurevic, Ilya and Meudec, Loic and Mariette, Xavier and Nocturne, Gaetane and McCoy, Sara S},
  title = {JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {e0311706},
  doi = {10.1371/journal.pone.0311706}
}
Kostenlos starten →